nach oben

Erschienen in:

09.11.2021 | Letter to the Editors

Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11–13 2019, Verona, Italy

verfasst von: Matteo Bellone, Marco Bregni, Vincenzo Bronte, Stefano Ugel, Pier Francesco Ferrucci, Massimo Di Nicola, Paola Nisticò, Gaia Zuccolotto, Antonio Rosato, Vincenzo Russo, Antonio Sica, Mario P. Colombo

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Excerpt

Oncology embrace Immunology: the way forward captioned the XVII international meeting of the Italian Network for Tumor Biotherapy (NIBIT) held in Verona on October 11–13, 2019. In reporting below the excellence of the scientific program, we cannot refrain from recalling the beauty and the enjoyment of getting together for science education and promotion in a spirit of friendship and freedom. Participants also experienced the enchantment of the town celebrated by Shakespeare in Romeo and Juliet, which is also the capital of open-air lyric at the Romanic Arena, and the perfect place to taste the regional cuisine and the excellent Ripasso and Amarone wines. …

Petitprez F, de Reynies A, Keung EZ et al (2020) B cells are associated with survival and immunotherapy response in sarcoma. Nature 577:556–560. https://doi.org/10.1038/s41586-019-1906-8CrossRefPubMed

Roumenina LT, Daugan MV, Noe R et al (2019) Tumor cells hijack macrophage-produced complement C1q to promote tumor growth. Cancer Immunol Res 7:1091–1105. https://doi.org/10.1158/2326-6066.CIR-18-0891CrossRefPubMed

Lienart S, Merceron R, Vanderaa C et al (2018) Structural basis of latent TGF-beta1 presentation and activation by GARP on human regulatory T cells. Science 362:952–956. https://doi.org/10.1126/science.aau2909CrossRefPubMed

de Streel G, Bertrand C, Chalon N et al (2020) Selective inhibition of TGF-beta1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer. Nat Commun 11:4545. https://doi.org/10.1038/s41467-020-17811-3CrossRefPubMedPubMedCentral

Kalafati L, Kourtzelis I, Schulte-Schrepping J et al (2020) Innate immune training of granulopoiesis promotes anti-tumor activity. Cell 183(771–85):e12. https://doi.org/10.1016/j.cell.2020.09.058CrossRef

Calderaro J, Petitprez F, Becht E et al (2019) Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. J Hepatol 70:58–65. https://doi.org/10.1016/j.jhep.2018.09.003CrossRefPubMed

Sautes-Fridman C, Petitprez F, Calderaro J, Fridman WH (2019) Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer 19:307–325. https://doi.org/10.1038/s41568-019-0144-6CrossRefPubMed

Di Modugno F, Spada S, Palermo B et al (2018) hMENA isoforms impact NSCLC patient outcome through fibronectin/beta1 integrin axis. Oncogene 37:5605–5617. https://doi.org/10.1038/s41388-018-0364-3CrossRefPubMedPubMedCentral

Rosenthal R, Cadieux EL, Salgado R et al (2019) Neoantigen-directed immune escape in lung cancer evolution. Nature 567:479–485. https://doi.org/10.1038/s41586-019-1032-7CrossRefPubMedPubMedCentral

10.

Eoli M, Corbetta C, Anghileri E et al (2019) Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy. Neurooncol Adv. 1:22. https://doi.org/10.1093/noajnl/vdz022CrossRef

11.

Norelli M, Camisa B, Barbiera G et al (2018) Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24:739–748. https://doi.org/10.1038/s41591-018-0036-4CrossRefPubMed

12.

Porcellini S, Asperti C, Corna S, Cicoria E, Valtolina V, Stornaiuolo A, Valentinis B, Bordignon C, Traversari C (2020) CAR T cells redirected to CD44v6 control tumor growth in lung and ovary adenocarcinoma bearing mice. Front Immunol 11:99. https://doi.org/10.3389/fimmu.2020.00099CrossRefPubMedPubMedCentral

13.

Sabatino M, Hu J, Sommariva M et al (2016) Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood 128:519–528. https://doi.org/10.1182/blood-2015-11-683847CrossRefPubMedPubMedCentral

14.

Montagner IM, Penna A, Fracasso G, Carpanese D, Dalla Pieta A, Barbieri V, Zuccolotto G, Rosato A (2020) Anti-PSMA CAR-engineered NK-92 cells: an off-the-shelf cell therapy for prostate cancer. Cells. https://doi.org/10.3390/cells9061382CrossRefPubMedPubMedCentral

15.

Advani R, Flinn I, Popplewell L et al (2018) CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med 379:1711–1721. https://doi.org/10.1056/NEJMoa1807315CrossRefPubMedPubMedCentral

16.

Vanpouille-Box C, Alard A, Aryankalayil MJ et al (2017) DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun 8:15618. https://doi.org/10.1038/ncomms15618CrossRefPubMedPubMedCentral

17.

Diamond JM, Vanpouille-Box C, Spada S et al (2018) Exosomes shuttle TREX1-sensitive IFN-stimulatory dsDNA from irradiated cancer cells to DCs. Cancer Immunol Res 6:910–920. https://doi.org/10.1158/2326-6066.CIR-17-0581CrossRefPubMedPubMedCentral

18.

Formenti SC, Rudqvist NP, Golden E et al (2018) Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med 24:1845–1851. https://doi.org/10.1038/s41591-018-0232-2CrossRefPubMedPubMedCentral

19.

Gandhi L, Rodriguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092. https://doi.org/10.1056/NEJMoa1801005CrossRefPubMed

20.

Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378:2288–2301. https://doi.org/10.1056/NEJMoa1716948CrossRefPubMed

21.

Etxeberria I, Bolanos E, Quetglas JI et al (2019) Intratumor adoptive transfer of IL-12 mRNA transiently engineered antitumor CD8(+) T cells. Cancer Cell 36(613–29):e7. https://doi.org/10.1016/j.ccell.2019.10.006CrossRef

22.

Perez-Ruiz E, Minute L, Otano I et al (2019) Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 569:428–432. https://doi.org/10.1038/s41586-019-1162-yCrossRefPubMed

23.

Schalper KA, Carleton M, Zhou M et al (2020) Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med 26:688–692. https://doi.org/10.1038/s41591-020-0856-xCrossRefPubMedPubMedCentral

24.

Kallikourdis M (2018) T cell responses to tumor: how dominant assumptions on immune activity led to a neglect of pathological functions, and how evolutionary considerations can help identify testable hypotheses for improving immunotherapy. Cancer Immunol Immunother 67:989–998. https://doi.org/10.1007/s00262-017-2113-9CrossRefPubMed

25.

Bellone M, Brevi A, Huber S (2020) Microbiota-propelled T helper 17 cells in inflammatory diseases and cancer. Microbiol Mol Biol Rev. https://doi.org/10.1128/MMBR.00064-19CrossRefPubMedPubMedCentral

26.

Sommariva M, Le Noci V, Bianchi F, Camelliti S, Balsari A, Tagliabue E, Sfondrini L (2020) The lung microbiota: role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy. Cell Mol Life Sci 77:2739–2749. https://doi.org/10.1007/s00018-020-03452-8CrossRefPubMedPubMedCentral

27.

Blank CU, Rozeman EA, Fanchi LF et al (2018) Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 24:1655–1661. https://doi.org/10.1038/s41591-018-0198-0CrossRefPubMed

28.

Rozeman EA, Menzies AM, van Akkooi ACJ et al (2019) Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol 20:948–960. https://doi.org/10.1016/S1470-2045(19)30151-2CrossRefPubMed

29.

Versluis JM, Long GV, Blank CU (2020) Learning from clinical trials of neoadjuvant checkpoint blockade. Nat Med 26:475–484. https://doi.org/10.1038/s41591-020-0829-0CrossRefPubMed

30.

Ascierto PA, Ferrucci PF, Fisher R et al (2019) Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med 25:941–946. https://doi.org/10.1038/s41591-019-0448-9CrossRefPubMed

31.

Minute L, Teijeira A, Sanchez-Paulete AR et al (2020) Cellular cytotoxicity is a form of immunogenic cell death. J Immunother Cancer. https://doi.org/10.1136/jitc-2019-000325CrossRefPubMedPubMedCentral

32.

Majorini MT, Cancila V, Rigoni A et al (2020) Infiltrating mast cell-mediated stimulation of estrogen receptor activity in breast cancer cells promotes the luminal phenotype. Cancer Res 80:2311–2324. https://doi.org/10.1158/0008-5472.CAN-19-3596CrossRefPubMed

33.

Truffi M, Colombo M, Sorrentino L et al (2018) Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells. Sci Rep 8:6563. https://doi.org/10.1038/s41598-018-24968-xCrossRefPubMedPubMedCentral

34.

Mosele F, Remon J, Mateo J et al (2020) Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. https://doi.org/10.1016/j.annonc.2020.07.014CrossRefPubMed

35.

Protti MP, De Monte L (2020) Dual role of inflammasome adaptor ASC in cancer. Front Cell Dev Biol 8:40. https://doi.org/10.3389/fcell.2020.00040CrossRefPubMedPubMedCentral

36.

Brunetto E, De Monte L, Balzano G et al (2019) The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer. J Immunother Cancer 7:45. https://doi.org/10.1186/s40425-019-0521-4CrossRefPubMedPubMedCentral

37.

Calcinotto A, Spataro C, Zagato E et al (2018) IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature 559:363–369. https://doi.org/10.1038/s41586-018-0266-0CrossRefPubMedPubMedCentral

38.

Bulgarelli J, Tazzari M, Granato AM et al (2019) Dendritic cell vaccination in metastatic melanoma turns “non-T cell inflamed” into “T-cell inflamed” tumors. Front Immunol 10:2353. https://doi.org/10.3389/fimmu.2019.02353CrossRefPubMedPubMedCentral

39.

Matet A, Ait Rais K, Malaise D et al (2019) Comparative cytogenetic abnormalities in paired choroidal melanoma samples obtained before and after proton beam irradiation by transscleral fine-needle aspiration biopsy and endoresection. Cancers (Basel). https://doi.org/10.3390/cancers11081173CrossRef

40.

Damato BE, Dukes J, Goodall H, Carvajal RD (2019) Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma. Cancers (Basel). https://doi.org/10.3390/cancers11070971CrossRef

Titel: Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11–13 2019, Verona, Italy
verfasst von: Matteo Bellone
Marco Bregni
Vincenzo Bronte
Stefano Ugel
Pier Francesco Ferrucci
Massimo Di Nicola
Paola Nisticò
Gaia Zuccolotto
Antonio Rosato
Vincenzo Russo
Antonio Sica
Mario P. Colombo
Publikationsdatum: 09.11.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 7/2022
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-021-03104-1

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

ASS schützt nicht vor Brustkrebsrezidiven

02.05.2024 Mammakarzinom Nachrichten

Nützt nichts und ist vielleicht sogar schädlich: In einer Phase-3-Studie konnten täglich 300 mg ASS keine Brustkrebsrezidive bei Frauen vermeiden, die ein hohes Risiko für eine Tumorrückkehr aufwiesen. Tendenziell traten unter ASS sogar häufiger Rezidive auf als unter Placebo.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11–13 2019, Verona, Italy

Excerpt

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

ASS schützt nicht vor Brustkrebsrezidiven

Update Onkologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2022

Distribution, phenotype, functional and clinical relevance of CD8+CD103+ tissue-resident memory T cells in human gastric cancer

Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study

Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab

Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15–16, 2020

Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis

Efficient adoptive transfer of autologous modified B cells: a new humanized platform mouse model for testing B cells reprogramming therapies

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

ASS schützt nicht vor Brustkrebsrezidiven

Update Onkologie